Vincristine in childhood leukaemia: No pharmacokinetic rationale for dose reduction in adolescents

Acta Paediatrica, International Journal of Paediatrics

Volumn 92, Issue 5, 2003, Pages 551-557

  Frost, B M ^a   Lönnerholm, Gudmar ^a   Koopmans, P ^b   Abrahamsson, J ^a,c   Behrendtz, M ^d   Castor, A ^e   Forestier, E ^f   Uges, D R A ^b   De Graaf, S S N ^g,h  

^a UNIVERSITY CHILDREN S HOSPITAL   (Sweden)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f UMEÅ UNIVERSITY   (Sweden)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Acute lymphoblastic leukaemia; Children; Pharmacokinetics; Vincristine

Indexed keywords

VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; AGE; AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; PRIORITY JOURNAL;

ADOLESCENT; AGE FACTORS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; VINCRISTINE;

EID: 10744227496     PISSN: 08035253     EISSN: None     Source Type: Journal    
DOI: 10.1080/08035350310011470     Document Type: Article

References (33)

1. Costa G, Hreshchyshyn, Holland J. Initial studies with vincristine. Cancer Chemother Rep 1962; 24: 39-43.
2. Johnson I, Armstrong J, Gorman M. The vinca alkaloids: a new class of oncolytic agents. Cancer Res 1963; 23: 1390-427.
3. Karon M, Freireich E, Frei E. A preliminary report on vincristine sulfate - a new active agent for the treatment of acute leukemia. Pediatr 1962; 30: 791-802.
4. Allen JC. The effects of cancer therapy on the nervous system. J Pediatr 1978; 93: 903-9.
5. Legha SS. Vincristine neurotoxicity. Pathophysiology and management. Med Toxicol 1986; 1: 421-7.
6. Hussain M, Wozniak AJ, Edelstein MB. Neurotoxicity of antineoplastic agents. Crit Rev Oncol Hematol 1993; 14: 61-75.
7. Gidding CE, Kellie SJ, Kamps WA, de Graaf SS. Vincristine revisited. Crit Rev Oncol Hematol 1999; 29: 267-87.
8. McCune JS, Lindley C. Appropriateness of maximum-dose guidelines for vincristine. Am J Health Syst Pharm 1997; 54: 1755-8.
9. Schwartz C, Smith J, Piantadosi S. Effect of vincristine dose on outcome in childhood ALL. Proc Am Soc Clin Oncol 1996; 15: 366.
10. Bender RA, Castle MC, Margileth DA, Oliverio VT. The pharmacokinetics of [3H]-vincristine in man. Clin Pharmacol Ther 1977; 22: 430-5.
11. Sethi VS, Jackson DV, Jr, White DR, Richards F, II, Stuart JJ, Muss HB, et al. Pharmacokinetics of vincristine sulfate in adult cancer patients. Cancer Res 1981; 41: 3551-5.
12. Crom WR, Glynn-Barnhart AM, Rodman JH, Teresi ME, Kavanagh RE, Christensen ML, et al. Pharmacokinetics of anticancer drugs in children. Clin Pharmacokinet 1987; 12: 168-213.
13. Bloemhof H, Van Dijk KN, De Graaf SS, Vendrig DE, Uges DR. Sensitive method for the determination of vincristine in human serum by high-performance liquid chromatography after on-line column-extraction. J Chromatogr 1991; 572: 171-9.
14. Gidding CE, Meeuwsen-de Boer GJ, Koopmans P, Uges DR, Kamps WA, de Graaf SS, et al. Vincristine pharmacokinetics after repetitive dosing in children. Cancer Chemother Pharmacol 1999; 44: 203-9.
15. Crom WR, de Graaf SS, Synold T, Uges DR, Bloemhof H, Rivera G, et al. Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. J Pediatr 1994; 125: 642-9.
16. de Graaf SS, Bloemhof H, Vendrig DE, Uges DR. Vincristine disposition in children with acute lymphoblastic leukemia. Med Pediatr Oncol 1995; 24: 235-40.
17. Chan JD. Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports. Pharmacotherapy 1998; 18: 1304-7.
18. Groninger E, Meeuwsen-De Boar T, Koopmans P, Uges D, Sluiter W, Veerman A, et al. Pharmacokinetics of vincristine monotherapy in childhood acute lymphoblastic leukemia. Pediatr Res 2002; 52: 113-8.
19. Gustafsson G, Schmiegelow K, Forestier E, Clausen N, Glomstein A, Jonmundsson G, et al. Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia 2000; 14: 2267-75.
20. D'Argenio D. Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm 1981; 9: 739-56.
21. Koopmans P, Gidding CE, de Graaf SS, Uges DR. An automated method for the bioanalysis of vincristine suitable for therapeutic drug monitoring and pharmacokinetic studies in young children. Ther Drug Monit 2001; 23: 406-9.
22. D'Argenio D, Schumitzky A. A program package for simulation and parameter estimination in pharmacokinetic systems. Comput Programs Biomed 1979; 9: 115-34.
23. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med 1987; 317: 1098.
24. Frost BM, Eksborg S, Bjork O, Abrahamsson J, Behrendtz M, Castor A, et al. Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative study. Med Pediatr Oncol 2002; 38: 329-37.
25. Casey EB, Jellife AM, Le Quesne PM, Millett YL. Vincristine neuropathy. Clinical and electrophysiological observations. Brain 1973; 96: 69-86.
26. Desai ZR, Van den Berg HW, Bridges JM, Shanks RG. Can severe vincristine neurotoxicity be prevented? Cancer Chemother Pharmacol 1982; 8: 211-4.
27. Rahmani R, Zhou XJ. Pharmacokinetics and metabolism of vinca alkaloids. Cancer Surv 1993; 17: 269-81.
28. Kamaluddin M, McNally P, Breatnach F, O'Marcaigh A, Webb D, O'Dell E, et al. Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies. Acta Pædiatr 2001; 90: 1204-7.
29. Murphy JA, Ross LM, Gibson BE. Vincristine toxicity in five children with acute lymphoblastic leukaemia. Lancet 1995; 346: 443.
30. Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996; 14: 18-24.
31. Schrappe M, Camitta B, Pui CH, Eden T, Gaynon P, Gustafsson G, et al. Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia 2000; 14: 2193-4.
32. Mastrangelo R, Poplack D, Bleyer A, Riccardi R, Sather H, D'Angio G. Report and recommendations of the Rome workshop concerning poor-prognosis acute lymphoblastic leukemia in children: biologic bases for staging, stratification, and treatment. Med Pediatr Oncol 1986; 14: 191-4.
33. Veerman AJ, Hahlen K, Kamps WA, Van Leeuwen EF, De Vaan GA, Solbu G, et al. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol 1996; 14: 911-8